目的:观察替米沙坦治疗肾性高血压患者对患者性功能的影响,为临床选择替米沙坦治疗肾性高血压患者提供参考.方法:选择2015年10月至2016年3月我院收治的120例初诊肾性高血压患者,根据就诊入组顺序将其编号,采用数字随机表法将其随机分为对照组和观察组,每组60例.两组患者均根据原发疾病对症治疗肾脏病变,并对患者进行血压控制饮食和运动的健康指导,对照组患者采用贝那普利控制血压,观察组采用替米沙坦控制血压,两组患者连续治疗6个月.比较两组患者治疗前后的尿微量白蛋白及肌酐变化,治疗前后性功能相关评分.男性采用勃起功能评分表(IIEF-5)和射精功能评分表(CI-PE)评分判断性功能的影响,女性采用女性性功能指数评估量表(FSFI)评判患者性功能影响.结果:试验组与对照组治疗前尿微量白蛋白和肌酐水平比较差异无统计学意义(P＞0.05);治疗后,两组患者微量尿蛋白均较治疗前明显下降,肌酐较治疗前明显上升,但观察组患者尿微量白蛋白低于对照组.对照组患者治疗前后男性IIEF-5和CIPE评分较治疗前明显下降,治疗前后比较差异有统计学意义(P＜0.05),女性治疗前后FSFI评分变化无统计学差异;观察组患者治疗后男性IIEF-5和CIPE评分与治疗前比较略有升高,但差异无统计学意义(P＞0.05),女性治疗前后FSFI评分变化无统计学差异(P＞0.05).结论:替米沙坦控制肾性高血压患者血压,不会对对患者的肾功能产生损害,同时也不降低患者的性功能,避免了大多数抗高血压药物存在的缺陷,对提升患者的生活质量具有较高的临床价值.%Objectives:To observe effect of telmisartan on sexual function of patients with renal hypertension,so as to provide reference for clinical selection of telmisartan in the treatment of patients with renal hypertension.Methods:120 patients with renal hypertension from October 2015 to March 2016 in our hospital were selected and randomly divided into control group and observation group,with 60 cases in each group.The control group was treated by Benner Pury for blood pressure control and observation group was treated by telmisartan for blood pressure control,both for 6-month continuous treatment.The changes in urinary micro albumin and serum creatinine before and after treatment of two groups were compared.Male erectile function rating scale (IIEF-5) and ejaculation function score (CIPE) were used to determine the sexual function of male patients and FSFI-women's sexual function index was used to assess sexual function of female patient.Results:The urinary albumin and creatinine levels of observation group and control group before treatment had no significant difference (P ＞ 0.05).After treatment,microalbuminuria levels of two groups were significantly decreased compared with that before treatment,and serum creatinine levels were significantly increased.The microalbuminuria level of observation group was lower than that of control group.The IIEF-5 and CIPE score of control group was significantly lower than that before treatment,with statistically significant difference (P ＜ 0.05).The changes in FSFI score had no significant difference;IIEF-5 and CIPE score of observation group after the treatment increased slightly,but the difference was not statistically significant (P ＞ 0.05),and the change in FSFI score had no significant difference (P ＞ 0.05).Conclusion:Telmisartan for blood pressure control in patients with renal hypertension has no harm to renal function of patients and doesn't reduce sexual function of patients,which avoids the defects that most antihypertensive drugs exist,with high clinical value of improving the quality of sex life of patients.
展开▼
